Literature DB >> 8392891

The carrier state in foot and mouth disease--an immunological review.

J S Salt1.   

Abstract

The carrier state in foot and mouth disease (FMD) is characterized by the asymptomatic low-level excretion of foot and mouth disease virus (FMDV) from the oropharynx of ruminants for periods that are species and virus strain-dependent. Persistent infection with FMDV readily occurs following the failure of virus elimination at the acute stage of infection, a process thought to be mediated through the phagocytosis of antibody/virus immune complexes. Recent evidence supports the view that carrier cattle are important in the epidemiology of FMD in the field. The absence of histopathological change in persistently infected tissues and the reduced cytopathology of carrier virus isolates in tissue culture suggest that less lytic FMDV variants are generated or selected in the carrier animal. Altered virus replication, due to attenuation or interference, rather than antigenic variation may therefore allow evasion of the exaggerated FMDV-specific systemic and local humoral immune responses that occur in the carrier state. Although cell-mediated immune mechanisms for FMDV clearance have not been described, the eventual elimination of many persistent virus infections involves this arm of the immune system. Thus, further investigation of cellular elements of the immune response, more particularly the local interaction of mononuclear cell infiltrates with persistently infected cells, represents an area of research that has the potential to elucidate the carrier state problem.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392891     DOI: 10.1016/S0007-1935(05)80168-X

Source DB:  PubMed          Journal:  Br Vet J        ISSN: 0007-1935


  49 in total

Review 1.  Foot-and-mouth disease.

Authors:  Marvin J Grubman; Barry Baxt
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

2.  Virulence as a positive trait in viral persistence.

Authors:  J C Sáiz; E Domingo
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

Review 3.  Within host RNA virus persistence: mechanisms and consequences.

Authors:  Richard E Randall; Diane E Griffin
Journal:  Curr Opin Virol       Date:  2017-03-17       Impact factor: 7.090

4.  Development of reverse transcription-PCR (oligonucleotide probing) enzyme-linked immunosorbent assays for diagnosis and preliminary typing of foot-and-mouth disease: a new system using simple and aqueous-phase hybridization.

Authors:  S Alexandersen; M A Forsyth; S M Reid; G J Belsham
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

Review 5.  A review of the possible mechanisms for the persistence of foot-and-mouth disease virus.

Authors:  E L Woodbury
Journal:  Epidemiol Infect       Date:  1995-02       Impact factor: 2.451

6.  Evidence for positive selection in foot-and-mouth disease virus capsid genes from field isolates.

Authors:  D T Haydon; A D Bastos; N J Knowles; A R Samuel
Journal:  Genetics       Date:  2001-01       Impact factor: 4.562

7.  Ability of foot-and-mouth disease virus to form plaques in cell culture is associated with suppression of alpha/beta interferon.

Authors:  J Chinsangaram; M E Piccone; M J Grubman
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

8.  Propagation of an attenuated virus by design: engineering a novel receptor for a noninfectious foot-and-mouth disease virus.

Authors:  E Rieder; A Berinstein; B Baxt; A Kang; P W Mason
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

9.  New vaccine design based on defective genomes that combines features of attenuated and inactivated vaccines.

Authors:  Teresa Rodríguez-Calvo; Samuel Ojosnegros; Marta Sanz-Ramos; Juan García-Arriaza; Cristina Escarmís; Esteban Domingo; Noemí Sevilla
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.240

10.  Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide.

Authors:  Carolina Cubillos; Beatriz G de la Torre; Annamaria Jakab; Giorgia Clementi; Eva Borrás; Juan Bárcena; David Andreu; Francisco Sobrino; Esther Blanco
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.